| Expression pattern: |
UP |
| Associated gene: |
CDK6, Rb, CDK6/Rb |
| Associated microRNA: |
miR-200a-3p |
| Biological function: |
Promotes HCC cell proliferation and increases S-phase fraction via CDK6/Rb regulation. |
| Molecular mechanism: |
Acts as a miRNA sponge for miR-200a-3p, relieving miR-200a-3p-mediated repression of CDK6 (via CDK6 3′UTR), leading to increased CDK6 and downstream Rb phosphorylation. |
| Biological pathway or process: |
proliferation (promotes); cell cycle (promotes); ceRNA regulation (promotes) |
| Detected method: |
Q
|
| Validation methods: |
RT-qPCR; RNA Pull-Down; Luciferase Reporter Assay; Transfection; CCK8; Cell Cycle Assay; Western Blot; IHC (Immunohistochemistry); Clinical Sample Validation; Cohort Study; Survival Analysis; Bioinformatics Analysis |
| Clinical significance: |
Tissue and serum circ-ZEB1.33 are associated with TMN stages and prognosis; serum circ-ZEB1.33 is a potentially valuable biomarker for HCC diagnosis and prognosis prediction. |
| Description: |
circ-ZEB1.33 is up-regulated in HCC tumor tissue and patient serum, promotes HCC cell proliferation and S-phase entry. Mechanistically, it sponges miR-200a-3p to de-repress CDK6 (and downstream Rb phosphorylation), and higher circ-ZEB1.33 is associated with advanced TMN stage and worse survival, supporting biomarker potential. |
| Confidence score: |
0.7853 |